Today: 19 April 2026
Beazley share price today rises as Zurich takeover clock ticks toward Feb 16 deadline
21 January 2026
2 mins read

Beazley share price today rises as Zurich takeover clock ticks toward Feb 16 deadline

London, Jan 21, 2026, 08:42 GMT — Regular session

  • Beazley shares rose 0.5% in early London trading, yet remain far below Zurich’s 1,280p cash offer
  • Beazley urges shareholders to hold off on any moves, noting the board hasn’t reviewed the improved offer yet
  • Traders are eyeing a solid bid — or a possible walkaway — as the Feb. 16 takeover-code deadline looms

Beazley (BEZ.L) shares ticked up 0.5% to 1,132 pence by 0842 GMT, staying close to the midpoint of the range established after Zurich Insurance Group revealed its bid.

That price puts the stock roughly 12% shy of Zurich’s 1,280 pence-a-share offer. Investors are focused on the difference — known in takeover lingo as the “deal spread” — nearly as much as on the insurer’s regular operations.

Beazley urged shareholders to hold fire, noting the board has yet to review Zurich’s updated offer. Per the UK Takeover Code, Zurich must decide by 5 p.m. London time on Feb. 16: either make a firm, binding bid or declare they won’t move forward. The Takeover Panel could extend this deadline.

Zurich proposed a 12.80-pound bid, marking a 56% premium over Beazley’s closing price on Jan. 16, following Beazley’s rejection of an earlier 1,230 pence offer. The company also warned that the final offer price would be lowered by any dividends declared or paid after the announcement.

The offer values Beazley at around £7.67 billion ($10.3 billion). Zurich plans to finance the deal through a combination of cash, new debt, and an equity placing — meaning it will sell new shares to investors. Jefferies analysts described the premium as “generous.” Shares of London-listed rivals Hiscox and Lancashire climbed on speculation of broader consolidation, while Zurich’s stock dipped. Reuters

Beazley surged over 40% in Monday’s session following news of the approach, only to give back 3.76% on Tuesday, closing at £11.26. Trading volume stayed notably high.

Should the Beazley bid fall through, Zurich has a backup plan to enter Lloyd’s of London. The Financial Times says it’s set to launch its inaugural Lloyd’s syndicate — essentially an underwriting vehicle within the market — possibly as early as April 2.

Beazley has kicked off the usual paperwork linked to an active takeover. It revealed there were 599,509,906 ordinary shares outstanding as of the close on Jan. 19, in line with Rule 2.9 of the Takeover Code.

Zurich CEO Mario Greco shifted the ball to investors. “I made an offer, it’s distant from being accepted, and now the shareholders have to speak about it,” he said in a phone interview. SWI swissinfo.ch

Yet the gap between the current price and the offer suggests investors aren’t convinced the deal will close. Beazley might push for a higher bid, a competitor could emerge, or Zurich might deem the price too high — sending shares sliding back toward the pre-bid range around 820 pence.

Traders are holding out for new comments from either party and the mandatory disclosures from big investors and advisers as positions evolve. The key date is still Feb. 16, when Zurich has to decide if it will turn talks into a binding offer.

Stock Market Today

  • Wipro Limited Earnings Steady; Analysts Trim Price Target to ₹210 Post-Results
    April 18, 2026, 10:56 PM EDT. Wipro Limited's latest earnings report showed revenues of ₹926 billion and earnings per share (EPS) of ₹12.56, meeting analyst expectations. Following the results, 38 analysts forecast a revenue increase of 7.2% to ₹993.4 billion and an EPS rise of 8.8% to ₹13.70 by 2027. Despite stable earnings projections, the consensus price target for Wipro shares dropped by 5.4% to ₹210, reflecting tempered optimism. The demand outlook appears positive with expected revenue growth outpacing the company's five-year average and industry peers, indicating stronger momentum. Analyst valuations range between ₹170 and ₹255, signaling some variation but overall confidence in Wipro's growth trajectory.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Glencore stock rises as Rio output beat keeps merger spotlight on miners
Previous Story

Glencore stock rises as Rio output beat keeps merger spotlight on miners

United Airlines stock pops in premarket after UAL lifts 2026 profit outlook — what investors watch next
Next Story

United Airlines stock pops in premarket after UAL lifts 2026 profit outlook — what investors watch next

Go toTop